Unlocking the potential of
genomic medicine

2017 News Releases

Webcast ImageWebcast
Aevi Genomic Medicine, Inc. at Leerink Partners 6th Annual Global Healthcare Conference (Replay)
02/16/17 at 10:30 a.m. ET
Aevi Genomic Medicine, Inc. at Leerink Partners 6th Annual Global Healthcare Conference
Thursday, February 16, 2017 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Aevi Genomic Medicine, Inc. 2017 Investor Day (Live)
02/22/17 at 9:00 a.m. ET
Aevi Genomic Medicine, Inc. 2017 Investor Day
Wednesday, February 22, 2017 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/15/17Aevi Genomic Medicine Announces 2017 Investor Day
PHILADELPHIA, PA -- (Marketwired) -- 02/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced that it will host an Investor Day with senior management and key opinion leaders to discuss AEVI-001 and opportunities in the ADHD market. The event will be held at the NASDAQ Market Site in New York City on Wednesday, February 22, 2017 with breakfast beginning at 8:30 a.m. Eastern Time and speaker presentations beginning at 9:00 a.m. Eastern Time. The event will include present... 
Printer Friendly Version
02/09/17Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference
PHILADELPHIA, PA -- (Marketwired) -- 02/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 10:30 a.m. EST at the Lotte New York Palace, New York, NY. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.... 
Printer Friendly Version
01/31/17Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
PHILADELPHIA, PA -- (Marketwired) -- 01/31/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the first patient has been dosed in a Phase 1/2 clinical trial to assess the efficacy of its lead investigational drug, AEVI-001 (NFC-1), in children with 22q11.2 Deletion Syndrome (22q DS), a rare disorder caused by an abnormality found on the 22nd chromosome. The trial will evaluate the changes in symptoms associated with three neuropsychiatric disorders -- including... 
Printer Friendly Version
01/04/17Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Untitled Document PHILADELPHIA, PA--(Marketwired - Jan 4, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line results expected in Q1 2017 Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that enrollment is complete in the SAGA (Study of Adolescent Glutamate Receptor Network Copy Number Variant ADHD) trial. All ongoing patients are expected to continue through the follow-up period in order to complete the study. The Company anticipates announcing top-l... 
Printer Friendly Version